dactinomycin - CISMeF

Preferred Label : dactinomycin;

MeSH definition : A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015);

MeSH synonym : meractinomycin; Actinomycin D;

CISMeF synonym : lemery brand of dactinomycin; MSD brand of dactinomycin; merck brand of dactinomycin; merck frosst brand of dactinomycin; merck sharp & dohme brand of dactinomycin;

DeCS synonym : LyovacCosmegen; Lyovac Cosmegen;

MeSH Hyperonym : actinomycin;

MeSH hyponym : Ac-De; cosmegen; Cosmegen Lyovac; Lyovac, Cosmegen; Lyovac-Cosmegen; Lyovac Cosmegen; LyovacCosmegen;

MeSH CAS label : actinomycin d;

MeSH Related Number : 50-76-0 (Dactinomycin);

Registry Number MeSH : 50-76-0;

Wikipedia link : https://en.wikipedia.org/wiki/Dactinomycin;

Codes EINECS : 200-063-6;

Is substance : O;

UNII : 1CC1JFE158;

InChIKey : RJURFGZVJUQBHK-IIXSONLDSA-N;

Details

Origin ID

D003609;

UMLS CUI

C0010934;

ATC code(s)
- dactinomycin [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Actinomycin Antineoplastic Antibiotic [NCIt concept]
- actinomycin [Substance BNPC]
- actinomycines [ATC Code]
CISMeF manual mappings
- dactinomycin [Substance BNPC]
Exact mapping(s) to DCI
- dactinomycin [International Nonproprietary Name]
False automatic mappings
- AC Followed by Docetaxel Regimen [NCIt concept]
- Acd shelterin complex subunit and telomerase recruitment factor [OMIM gene]
- Adult form of celiac disease (disorder) [SNOMED CT concept]
- Amyloidosis, primary localized cutaneous, 3 [OMIM Phenotype]
- Coeliac disease [ICD-11 Category]
- Corneal dystrophy, avellino type [OMIM Phenotype]
- Suborder Actinomycineae (organism) [SNOMED CT concept]
Pharmacological action(s)
- anti-bacterial agents [MeSH Descriptor]
- antibiotics, antineoplastic [MeSH Descriptor]
- nucleic acid synthesis inhibitors [MeSH Descriptor]
- protein synthesis inhibitors [MeSH Descriptor]
Record concept(s)
- actinomycin [MeSH concept]
- cosmegen [MeSH concept]
- dactinomycin [MeSH concept]
Related MeSH Supplementary Concept(s)
- 1,1'-bis(L-alpha,beta-diaminopropionic acid)actinomycin D [MeSH Supplementary Concept]
- 7-(2,3-epoxypropoxy)actinomycin D [MeSH Supplementary Concept]
- 7-aminoactinomycin D [MeSH Supplementary Concept]
- 7-azidoactinomycin D [MeSH Supplementary Concept]
- 8-fluoro-actinomycin D [MeSH Supplementary Concept]
- ABV-ADV protocol [MeSH Supplementary Concept]
- AcFuCy protocol [MeSH Supplementary Concept]
- BAP protocol 2 [MeSH Supplementary Concept]
- BCD protocol [MeSH Supplementary Concept]
- BOP-CISCA-POMB-ACE regimen [MeSH Supplementary Concept]
- CHAMOCA regimen [MeSH Supplementary Concept]
- CHAMOMA protocol [MeSH Supplementary Concept]
- DD1 protocol [MeSH Supplementary Concept]
- EMA-CO protocol [MeSH Supplementary Concept]
- EMACO protocol [MeSH Supplementary Concept]
- FDV protocol [MeSH Supplementary Concept]
- IVA protocol [MeSH Supplementary Concept]
- MAC III protocol [MeSH Supplementary Concept]
- MAC combination [MeSH Supplementary Concept]
- MAE protocol [MeSH Supplementary Concept]
- MDC protocol [MeSH Supplementary Concept]
- MEA regimen [MeSH Supplementary Concept]
- MOFK protocol [MeSH Supplementary Concept]
- MOMK protocol [MeSH Supplementary Concept]
- N-(4-nitrobenzyloxycarbonyl)actinomycin D [MeSH Supplementary Concept]
- N8-actinomycin D [MeSH Supplementary Concept]
- PEA regimen [MeSH Supplementary Concept]
- PEA-M regimen [MeSH Supplementary Concept]
- POMB-ACE protocol [MeSH Supplementary Concept]
- POMB-ACE regimen [MeSH Supplementary Concept]
- POMB-ACE-PAV regimen [MeSH Supplementary Concept]
- SIOP protocol [MeSH Supplementary Concept]
- T-6 protocol [MeSH Supplementary Concept]
- T10 A protocol [MeSH Supplementary Concept]
- T7 protocol [MeSH Supplementary Concept]
- VAB II protocol [MeSH Supplementary Concept]
- VAB protocol [MeSH Supplementary Concept]
- VAB-6 regimen [MeSH Supplementary Concept]
- VAB-III protocol [MeSH Supplementary Concept]
- VAB-IV protocol [MeSH Supplementary Concept]
- VAC protocol [MeSH Supplementary Concept]
- VACA protocol [MeSH Supplementary Concept]
- VACAD protocol [MeSH Supplementary Concept]
- VAD regimen 2 [MeSH Supplementary Concept]
- VAIA protocol [MeSH Supplementary Concept]
- actinomine [MeSH Supplementary Concept]
- actinomycin C2 [MeSH Supplementary Concept]
- actinomycin C3 [MeSH Supplementary Concept]
- actinomycin D lactam [MeSH Supplementary Concept]
- actinomycin D, valyl(2,2')-N-methylleucyl(5,5')- [MeSH Supplementary Concept]
- actinomycin D-dATGCAT complex [MeSH Supplementary Concept]
- actinomycin D1 [MeSH Supplementary Concept]
- actinomycin D2 [MeSH Supplementary Concept]
- actinomycin G [MeSH Supplementary Concept]
- actinomycin K [MeSH Supplementary Concept]
- actinomycin S3 [MeSH Supplementary Concept]
- actinomycin V [MeSH Supplementary Concept]
- actinomycin VII [MeSH Supplementary Concept]
- actinomycin X [MeSH Supplementary Concept]
- actinomycin X2 [MeSH Supplementary Concept]
- actinomycinic acid [MeSH Supplementary Concept]
- aurantin [MeSH Supplementary Concept]
- azetomycins [MeSH Supplementary Concept]
- bis-actinomycin D [MeSH Supplementary Concept]
- cactinomycin [MeSH Supplementary Concept]
- chounghwamycin A [MeSH Supplementary Concept]
- desaminoactinomycin C [MeSH Supplementary Concept]
- dimethyl actinocynil bis(L-threonate) [MeSH Supplementary Concept]
- gluconimycin [MeSH Supplementary Concept]
- kengshenmycin [MeSH Supplementary Concept]
- levoristatin [MeSH Supplementary Concept]
- methylated actinomycin D [MeSH Supplementary Concept]
- rosen's T-10 protocol [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Antibiotic [UMLS semantic type]
UMLS correspondences (same concept)
- Dactinomycin [ICD-11 Extension code]
- Dactinomycin [NCIt concept]
- Dactinomycin (substance) [SNOMED CT concept]
- Product containing dactinomycin (medicinal product) [SNOMED CT concept]
- dactinomycin [ATC Code]
- dactinomycin [Substance BNPC]
- dactinomycin [SNOMED Notion]
- dactinomycin [International Nonproprietary Name]
Validated automatic mappings to BTNT
- dactinomycin [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients